|
DE1164829B
(de)
|
1961-04-26 |
1964-03-05 |
Bayer Ag |
Verfahren zur elektrophotographischen Herstellung von Bildern mit Fluessigkeitsaerosolen
|
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US5001116A
(en)
|
1982-12-20 |
1991-03-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
US4994443A
(en)
|
1982-12-20 |
1991-02-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
US4551177A
(en)
|
1984-04-23 |
1985-11-05 |
National Starch And Chemical Corporation |
Compressible starches as binders for tablets or capsules
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5391485A
(en)
|
1985-08-06 |
1995-02-21 |
Immunex Corporation |
DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
|
|
JPS63500636A
(ja)
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
|
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US5974203A
(en)
|
1988-04-11 |
1999-10-26 |
Canon Kabushiki Kaisha |
Pattern recognition communication apparatus for transmitting and receiving image data
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
CA2071479A1
(en)
|
1990-10-12 |
1992-04-13 |
Pamela Hunt |
Megakaryocyte maturation factors
|
|
US5387421A
(en)
|
1991-01-31 |
1995-02-07 |
Tsrl, Inc. |
Multi stage drug delivery system
|
|
AU1531492A
(en)
|
1991-02-14 |
1992-09-15 |
Rockefeller University, The |
Method for controlling abnormal concentration tnf alpha in human tissues
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
US5358941A
(en)
|
1992-12-02 |
1994-10-25 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids with lactose
|
|
US5360352A
(en)
|
1992-12-24 |
1994-11-01 |
The Whitaker Corporation |
Wire retainer for current mode coupler
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6114355A
(en)
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US20010056114A1
(en)
|
2000-11-01 |
2001-12-27 |
D'amato Robert |
Methods for the inhibition of angiogenesis with 3-amino thalidomide
|
|
US5594637A
(en)
|
1993-05-26 |
1997-01-14 |
Base Ten Systems, Inc. |
System and method for assessing medical risk
|
|
US5698579A
(en)
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
|
US5641758A
(en)
|
1993-11-10 |
1997-06-24 |
Kluge; Michael |
Cytarabine derivatives, the preparation and use thereof
|
|
US6432924B1
(en)
|
1993-12-26 |
2002-08-13 |
East Carolina University |
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
|
|
GB9412394D0
(en)
|
1994-06-21 |
1994-08-10 |
Danbiosyst Uk |
Colonic drug delivery composition
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
EP0800680A4
(en)
|
1994-10-28 |
1998-08-12 |
Advanced Health Med E Systems |
PRESCRIPTION MANAGEMENT SYSTEM
|
|
US5593696A
(en)
|
1994-11-21 |
1997-01-14 |
Mcneil-Ppc, Inc. |
Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
|
|
US5619991A
(en)
|
1995-04-26 |
1997-04-15 |
Lucent Technologies Inc. |
Delivery of medical services using electronic data communications
|
|
US5643915A
(en)
|
1995-06-06 |
1997-07-01 |
Andrulis Pharmaceuticals Corp. |
Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
|
|
US5731325A
(en)
|
1995-06-06 |
1998-03-24 |
Andrulis Pharmaceuticals Corp. |
Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
|
|
US5832449A
(en)
|
1995-11-13 |
1998-11-03 |
Cunningham; David W. |
Method and system for dispensing, tracking and managing pharmaceutical trial products
|
|
US6063026A
(en)
|
1995-12-07 |
2000-05-16 |
Carbon Based Corporation |
Medical diagnostic analysis system
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
|
DE69739802D1
(de)
|
1996-07-24 |
2010-04-22 |
Celgene Corp |
Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
|
|
ES2315435T3
(es)
|
1996-08-12 |
2009-04-01 |
Celgene Corporation |
Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
|
|
US5924074A
(en)
|
1996-09-27 |
1999-07-13 |
Azron Incorporated |
Electronic medical records system
|
|
EP1586322B1
(en)
|
1996-11-05 |
2008-08-20 |
The Children's Medical Center Corporation |
Compositions comprising thalodimide and dexamethasone for the treatment of cancer& x9;
|
|
US6131090A
(en)
|
1997-03-04 |
2000-10-10 |
Pitney Bowes Inc. |
Method and system for providing controlled access to information stored on a portable recording medium
|
|
ES2248908T7
(es)
|
1997-06-06 |
2014-11-24 |
Depomed, Inc. |
Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
AU8909898A
(en)
|
1997-08-22 |
1999-03-16 |
Deka Products Limited Partnership |
Health care system and method for physician order entry
|
|
US5874448A
(en)
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
|
US5955476A
(en)
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
US6096757A
(en)
|
1998-12-21 |
2000-08-01 |
Schering Corporation |
Method for treating proliferative diseases
|
|
ES2243052T3
(es)
|
1998-03-16 |
2005-11-16 |
Celgene Corporation |
Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
|
|
JPH11286455A
(ja)
|
1998-03-31 |
1999-10-19 |
Kanebo Ltd |
骨髄異形成症候群治療薬
|
|
US6673828B1
(en)
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
US6020358A
(en)
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
|
US20030013739A1
(en)
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
|
GB9904585D0
(en)
|
1999-02-26 |
1999-04-21 |
Gemini Research Limited |
Clinical and diagnostic database
|
|
TR200102688T2
(tr)
|
1999-03-18 |
2002-01-21 |
Celgene Corporation |
İkameli 1-okso ve 1,3-dioksoizoindolinler ve enflamatuar sitokin seviyelerinin azaltılması için farmasötik bileşimlerde kullanımları.
|
|
US20010021380A1
(en)
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
EP1236472A1
(en)
|
1999-07-16 |
2002-09-04 |
Amato Pharmaceutical Products, Ltd. |
Glycyrrhizin preparations for transmucosal absorption
|
|
US6202923B1
(en)
|
1999-08-23 |
2001-03-20 |
Innovation Associates, Inc. |
Automated pharmacy
|
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
|
CA2319872C
(en)
|
2000-02-02 |
2012-06-19 |
Chun-Ying Huang |
Pharmaceutical composition for the treatment of hepatocellular carcinoma
|
|
ES2270982T3
(es)
|
2000-02-04 |
2007-04-16 |
Depomed, Inc. |
Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
|
|
PL358335A1
(en)
|
2000-03-17 |
2004-08-09 |
Cell Therapeutics, Inc. |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
|
NZ521937A
(en)
|
2000-03-31 |
2004-08-27 |
Celgene Corp |
Inhibition of cyclooxygenase-2 activity
|
|
DE60118571T2
(de)
|
2000-05-15 |
2007-02-01 |
Celgene Corp. |
Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
|
|
CA2408710C
(en)
|
2000-05-15 |
2010-01-26 |
Celgene Corp. |
Compositions and methods for the treatment of colorectal cancer
|
|
AU2001280161A1
(en)
|
2000-08-24 |
2002-03-04 |
Kirin Beer Kabushiki Kaisha |
C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
CA2430669C
(en)
|
2000-11-30 |
2011-06-14 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
|
US20020128228A1
(en)
|
2000-12-01 |
2002-09-12 |
Wen-Jen Hwu |
Compositions and methods for the treatment of cancer
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
GB0102342D0
(en)
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
|
EP1389203B8
(en)
|
2001-02-27 |
2010-03-10 |
The Governement of the United States of America, represented by The Secretary Department of Health and Human services |
Analogs of thalidomide as angiogenesis inhibitors
|
|
WO2003014315A2
(en)
|
2001-08-06 |
2003-02-20 |
The Children's Medical Center Corporation |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
JP4027693B2
(ja)
|
2002-03-20 |
2007-12-26 |
トリニティ工業株式会社 |
塗料送給装置及びバルブユニット
|
|
US20030220254A1
(en)
|
2002-03-29 |
2003-11-27 |
Texas Tech University System |
Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
|
|
WO2003086373A1
(en)
|
2002-04-12 |
2003-10-23 |
Celgene Corporation |
Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
|
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US8263637B2
(en)
|
2002-05-17 |
2012-09-11 |
Celgene Corporation |
Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide
|
|
CN1981761B
(zh)
|
2002-05-17 |
2011-10-12 |
细胞基因公司 |
使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物
|
|
US8404717B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US20040091455A1
(en)
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
EP1556010A4
(en)
|
2002-10-31 |
2007-12-05 |
Supergen Inc |
PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
|
|
US20040152632A1
(en)
|
2002-11-06 |
2004-08-05 |
Wyeth |
Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US6887855B2
(en)
|
2003-03-17 |
2005-05-03 |
Pharmion Corporation |
Forms of 5-azacytidine
|
|
US6943249B2
(en)
|
2003-03-17 |
2005-09-13 |
Ash Stevens, Inc. |
Methods for isolating crystalline Form I of 5-azacytidine
|
|
CL2004001004A1
(es)
|
2003-05-19 |
2005-03-18 |
Upjohn Co |
Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
|
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
WO2005110408A1
(en)
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
|
CA2563207A1
(en)
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
|
US20060128654A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
|
US20070155791A1
(en)
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
|
US8058260B2
(en)
|
2006-05-22 |
2011-11-15 |
Xenoport, Inc. |
2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
|
|
PT2068874E
(pt)
|
2006-08-07 |
2015-05-21 |
Abbvie Biotherapeutics Inc |
Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi
|
|
CA2661983C
(en)
|
2006-08-30 |
2015-05-05 |
Mount Sinai School Of Medicine Of New York University |
Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
WO2008028193A2
(en)
|
2006-09-01 |
2008-03-06 |
Pharmion Corporation |
Colon-targeted oral formulations of cytidine analogs
|
|
LT2420498T
(lt)
|
2006-09-26 |
2017-10-25 |
Celgene Corporation |
5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
|
|
JP5637852B2
(ja)
|
2007-09-26 |
2014-12-10 |
セルジーン コーポレイション |
６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法
|
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain Compounds, Compositions and Methods
|
|
US20100311683A1
(en)
|
2007-11-01 |
2010-12-09 |
Beach C L |
Cytidine analogs for treatment of myelodysplastic syndromes
|
|
ES2774226T3
(es)
|
2008-05-15 |
2020-07-17 |
Celgene Corp |
Formulaciones orales de análogos de citidina y métodos de uso de los mismos
|
|
MX361467B
(es)
|
2008-10-29 |
2018-12-06 |
Celgene Corp |
Compuestos de isoindolina para uso en el tratamiento de cancer.
|
|
US8628927B2
(en)
|
2008-11-07 |
2014-01-14 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
|
EP3199149A1
(en)
|
2009-05-19 |
2017-08-02 |
Celgene Corporation |
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
|
|
PL2536706T3
(pl)
|
2010-02-11 |
2017-10-31 |
Celgene Corp |
Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
|
|
PT2683384E
(pt)
|
2011-03-11 |
2016-03-11 |
Celgene Corp |
Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
|
|
US20140142128A1
(en)
|
2012-11-20 |
2014-05-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
HK1246180A1
(zh)
*
|
2014-12-31 |
2018-09-07 |
Celgene Corporation |
使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
|
|
US9713375B1
(en)
|
2015-02-26 |
2017-07-25 |
Brett Einar Rahm |
Collapsible portable table
|
|
PL3313528T3
(pl)
*
|
2015-06-29 |
2021-12-13 |
Bristol-Myers Squibb Company |
Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka
|